When ischemic stroke patients do not receive intravelous alteplase to help dissolve clots, their odds of survival are significantly reduced, according to a study published in the American Journal of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Among patients with acute ischemic stroke ...

Patients with minor acute ischemic strokes and deficits that are not clearly disabling at presentation do not derive a benefit from IV alteplase, according to results of the PRISMS trial, which was ...

Outcomes after stroke thrombectomy were not better with tissue plasminogen activator (tPA) withheld, according to the MR CLEAN-NO IV trial. Of more than 500 acute stroke patients with large vessel ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- Dual ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers. Ischemic stroke patients who ...

Recent use of non-vitamin K antagonist oral anticoagulants (NOACs) is not associated with increased risk for bleeding following treatment with intravenous alteplase for ischemic stroke, new data ...

For patients who present to a thrombectomy-capable center, a direct trip to endovascular therapy does not improve functional outcomes compared with the guideline-recommended approach of giving IV ...

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

A major international analysis of 2,313 patients, median age 71, found that giving an IV clot-busting drug before mechanical clot removal modestly increases brain-bleeding risk compared with ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.